Randomized · Double-Blind · Placebo-Controlled

Among the most powerful cardiovascular improvements ever measured in a longevity supplement

In a university-run randomized clinical trial, NOVOS Core produced improvements in three key markers of vascular aging—exceeding the effect sizes reported in many studies of exercise, diet, and other supplements.

Buy NOVOS Core →

Learn about the clinical trial that set a new benchmark for longevity science

6-Month Clinical Results vs. Placebo

Three key markers. All improved.

In healthy adults aged 40+, NOVOS Core produced statistically significant improvements across three widely studied markers of cardiovascular aging biology, in a double-blind, randomized, placebo-controlled clinical study.

+2.9 %

Endothelial function improvement

Flow-mediated dilation (FMD)

Improvements of ~1% in FMD are considered clinically meaningful in vascular research.¹ By comparison, a study of aerobic exercise in a similar population improved FMD by 1.2%.

–1.2 m/s

Arterial flexibility improvement

Pulse wave velocity (PWV)

PWV typically worsens by about 1 m/s per decade of aging in adults.² A 1.2 m/s improvement vs. placebo was observed after 6 months. By comparison, a study of High Intensity Interval Training in a similar population improved PWV by -0.63 m/s.

–6.1 mmHg

Blood pressure reduction(for blood pressure already within the normal range)

Systolic blood pressure (SBP)

Epidemiological studies have found –2 mmHg in SBP is associated with meaningful differences in cardiovascular outcomes at the population level.³ By comparison, a study of dietary sodium reduction in a healthy population reduced systolic BP by 2.4 mmHg.

These biomarkers reflect complementary aspects of cardiovascular aging biology, including endothelial function, vascular flexibility, and systolic blood pressure regulation.

¹ Inaba Y et al., Int J Cardiovasc Imaging, 2010
² Vlachopoulos C et al., J Am Coll Cardiol, 2010
³ Lewington S et al., Lancet, 2002

"Taken together, improvements across endothelial function, arterial flexibility, and systolic blood pressure point to a coherent pattern consistent with a favorable shift in vascular aging biology."
Dr. Christian Heiss, MD
Professor of Cardiovascular Medicine, University of Surrey — Senior Author of the NOVOS Core study

*These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Primary Endpoint

FMD: The study's primary endpoint

Flow-mediated dilation (FMD) measures the ability of blood vessels to expand in response to increased blood flow — a key indicator of endothelial health and vascular function.

NOVOS Core significantly improved FMD both acutely (within 1 hour) and after 6 months of daily use, while the placebo group showed no meaningful change.

NOVOS

Placebo

* p < 0.001 vs. placebo (statistical significance)

Baseline Age Equivalence

40–60+

years

FMD levels typically observed in
mid-to-late adulthood

NOVOS Age Equivalence

(1 hour and 6 months)

20–30+

years

Levels typically observed in
younger adult populations

Age-equivalent ranges are descriptive comparisons based on published reference values for flow-mediated dilation (FMD) in healthy populations (Holder et al., 2021; Maruhashi et al., 2020). Values may vary by methodology and individual characteristics. Acute and longer-term measurements reflect different physiological states.

This study did not assess clinical outcomes. These results do not imply diagnosis, treatment, cure, prevention of disease, or reduction in disease risk.

Data from a double-blind, randomized, placebo-controlled clinical trial in healthy adults aged 40+. Error bars represent 95% confidence intervals.

Head-to-Head Comparisons

How NOVOS Core compares to leading interventions studied in similar populations

Results compared against published meta-analyses and randomized controlled trials of exercise, diet, and supplements in similar populations.

Sustained FMD improvement (%)

NOVOS Core2.9

Tea (green/black)2.3

Resistance training2.11

Blueberries2.01

CoQ101.69

Nitric oxide booster1.6

Folic acid1.51

Resveratrol1.4

Mediterranean diet1.3

Aerobic exercise1.2

Cocoa1.2

Flavonoids1.15

Severe weight loss1.1

Walnuts1.05

Flavan-3-ols1.02

Omega-31

Effect sizes are based on published clinical trials and meta-analyses reporting changes in similar biomarkers in adult populations.

Each 1% improvement in FMD has been associated with lower future cardiovascular risk in epidemiological studies.

These improvements were observed in healthy adults already within normal ranges, where further improvements are typically harder to achieve.

Improvements were observed in adults whose blood pressure was already within the normal range, where further improvements are typically harder to achieve.

"It has been a pleasure to watch NOVOS take a disciplined, biology-first approach, combined with a willingness to engage in rigorous evaluation rather than shortcuts, in a space that too often prioritizes hype over evidence."
Doina Kulick, M.D.
Lead Physician, Longevity Medicine Program at Mayo Clinic Arizona

The Organ That Ages First

Cardiovascular aging is systemic

Your heart and vascular system are among the first organs to show measurable signs of biological aging — and the most consequential.

3D visualization of the cardiovascular system

Why multi-endpoint results are noteworthy

Most supplement studies report changes in a single biomarker — and it's typically not a functional marker (one that measures organ function, rather than a proxy).

In this trial, NOVOS Core was associated with improvements across all three measured functional endpoints.

The biology

Cardiovascular aging involves interacting biological processes — including oxidative stress, mitochondrial dysfunction, inflammation, and impaired nitric oxide signaling.

The signal

Observing improvements across multiple aspects of cardiovascular function simultaneously may reflect a multi-pathway approach addressing upstream biology, rather than isolated downstream effects.

The design

NOVOS Core was not designed as a cardiovascular supplement. It was formulated around the 12 biological hallmarks of aging — targeting systemic aging biology.

Cardiovasculardiseaseistheleadingage-relatedcauseofdeathglobally

1.5–2×

Moredeathsannuallythancancer

7+ years

Ofresearchspanningmechanisticstudies,animalmodels,andnowahumanclinicaltrial

"I see NOVOS as inspiring — they approach aging as a complex phenomenon, aiming at all pathways and hallmarks of aging simultaneously."
Dr. George Church
Genetics Professor, Harvard Medical School & MIT

What leading scientists & MDs say

"This trial provides rare human evidence that a multi-pathway nutritional strategy can meaningfully influence cardiovascular aging biology itself. The magnitude and consistency of these effects across multiple cardiovascular endpoints is unusual for a nutritional intervention in a healthy population."
Dr. Christian Heiss, MD
Professor of Cardiovascular Medicine, University of Surrey — Senior Author of the NOVOS Core study

"It's the rigorously-researched, science-backed formulations that set NOVOS apart in the longevity supplements space."
Dr. Robert Lufkin, MD
Professor, USC School of Medicine

Recognized by clinicians and institutions

The scientific approach behind NOVOS has drawn attention from physicians and health institutions worldwide.

1,600+ MDs & clinicians share NOVOS Core
without compensation

"It has been a pleasure to watch NOVOS take a disciplined, biology-first approach, combined with a willingness to engage in rigorous evaluation rather than shortcuts, in a space that too often prioritizes hype over evidence."

DOINA KULICK, M.D.

LEAD PHYSICIAN, LONGEVITY MEDICINE PROGRAM AT MAYO CLINIC ARIZONA

NOVOS products are now available at world class hospitals and wellness retailers.

In the press

"NOVOS are pioneers in consumer longevity and among the first to develop a comprehensive approach that targets 12 mechanisms of aging simultaneously."

"A recent study places Novos Core as a leader among consumer antiaging interventions."

"A multi-ingredient longevity supplement made by the biotechnology company NOVOS may help improve markers of cardiovascular aging."

The clinical evidence speaks for itself

NOVOS Core is one of the only longevity supplements ever to demonstrate significant improvements across multiple validated markers of cardiovascular aging in a randomized, placebo-controlled human trial.

Buy NOVOS Core →

Read about the clinical study

*These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.